

Tenascin-C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma

SUPPLEMENTAL DIGITAL CONTENT

SUPPLEMENTARY TABLE 1. Associations Between Tenascin-C Expression, Fibronectin Expression, and Tumor-Stroma Ratio, and Clinicopathological Variables in 95 Pancreatic Ductal Adenocarcinoma Patients

Variable	n/N	Tenascin-C, n (%)			Fibronectin, n (%)			Tumor-stroma Ratio, n (%)		
		Low	High	P	Low	High	P	Low	High	P
pT				0.250			0.045			0.563
T1	6/95	6 (9)	0 (0)		6 (12)	0 (0)		3 (7)	3 (6)	
T2	30/95	22 (34)	8 (27)		17 (35)	13 (28)		10 (24)	20 (37)	
T3	52/95	33 (51)	19 (63)		24 (49)	28 (61)		24 (59)	28 (52)	
T4	7/95	4 (6)	3 (10)		2 (4)	5 (11)		4 (10)	3 (5)	
Lymph nodes*				0.162			0.262			0.126
Positive	51/95	32 (50)	11 (37)		24 (50)	19 (41)		19 (46)	32 (60)	
Negative	43/95	32 (50)	19 (63)		24 (50)	27 (59)		22 (54)	21 (40)	
Organ metastases				0.479			0.545			0.559
Positive	11/95	58 (89)	26 (88)		43 (88)	41 (89)		5 (12)	6 (11)	
Negative	84/95	7 (11)	4 (13)		6 (12)	5 (11)		36 (88)	48 (89)	
Stage*				0.304			0.136			0.670
I	18/95	15 (23)	3 (10)		13 (27)	5 (11)		7 (17)	11 (21)	
II	59/95	38 (59)	21 (70)		27 (56)	32 (70)		25 (61)	34 (64)	
III-IV	17/95	11 (17)	6 (20)		8 (17)	9 (20)		9 (22)	8 (15)	
Tumor size, mm†				0.163			0.167			0.124
<30	30/95	23 (36)	7 (23)		18 (38)	12 (26)		10 (24)	20 (38)	
≥30	64/95	41 (64)	23 (77)		30 (62)	34 (74)		31 (76)	33 (62)	
Perineural invasion				0.070			0.303			0.230
Absent	47/95	36 (55)	11 (37)		26 (53)	21 (46)		18 (44)	29 (54)	
Present	48/95	29 (45)	19 (63)		23 (47)	25 (54)		23 (56)	25 (46)	

Bold P values are statistically significant.

*Lymph node status was unavailable for one patient.

†Tumor size was unavailable for one patient.

pT indicates pathological T.